rttnews.comSep 9$MSLE

Satellos Names Forazapadin As INN For Lead DMD Drug Candidate

Satellos Bioscience (MSLE) announced the WHO assigned the INN forazapadin to its lead drug candidate, SAT-3247, for treating DMD and other muscle diseases. The company expects to complete enrollment in the BASECAMP Phase 2 study by Q3 2026 and release data in Q4. It also plans to start a Phase 2 trial for FSHD by year-end. The stock closed at $9.18, up 2.00%.

Original reporting

rttnews.com

Published Sep 9, 2026, 2:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 9, 2026, 2:39 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$MSLE

Bullish

medium confidence

Mentioned

$MSLE

Relevance

6/10

AlphAI data visualization · based on rttnews.com

Decision brief

The 30-second read

$MSLEBullishMed

Why it matters

The INN assignment signals regulatory progress and may improve market perception, but actual valuation impact depends on forthcoming trial data.

Market read

First disclosure of INN naming could modestly lift the stock ahead of Phase 2 readouts, relevant for biotech-focused traders.

What to watch

Potential competition from other DMD therapies and funding requirements for Phase 3.

Relevance 6/10Novelty 7/10Timing: today

Background

Satellos Bioscience announced WHO assignment of the INN "forazapadin" for its lead DMD candidate, SAT-3247, and outlined ongoing Phase 2 trials.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MSLEBullishMedium confidence

Context

Satellos Bioscience received WHO INN for its lead DMD candidate, indicating program maturity and upcoming data releases.

Expected impact

Modest upside potential as enrollment progresses.

Evidence & confidence

INN assignment is a first‑time disclosure that signals regulatory progress, but no data or financials are released yet.

Market effects

Sector

Highlights continued pipeline activity in the DMD biotech sector.

Regional

May attract interest from US biotech investors.

Global

Limited to niche rare‑disease investors.

Counterpoint

What could challenge this read

The naming alone may not translate into near‑term price movement without data.

Key entities

company
Satellos Bioscience Inc.
Biotech developing forazapadin for Duchenne muscular dystrophy.
organization
World Health Organization
Assigned the International Nonproprietary Name for the drug.

Read at source ← All news

$MSLEMedAI 8/10

Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results

Satellos Bioscience (NASDAQ: MSLE) announced trial endpoints for its Duchenne muscular dystrophy study after FDA discussions, aiming for 2027 results. The study will evaluate muscle function, strength, and biomarkers. The company cited preliminary support from a smaller study, TRAILHEAD, showing reduced biceps fat fraction and improved upper-limb function. Satellos plans to provide guidance on potential filing and commercialization in Q1 2027.

finance.yahoo.comNov 7

$MSLELow

Satellos Changes BASECAMP Endpoint After FDA Feedback; Data Expected In Q1 2027

Satellos Bioscience (MSLE) changed its Phase 2 BASECAMP study's primary endpoint to MRI-measured muscle fat fraction, following FDA feedback. The company expects topline results in Q1 2027. Earlier TRAILHEAD study showed a 3.7 percentage-point reduction in muscle fat fraction. MSLE stock is up 7.98%.

rttnews.comNov 6

$MSLEMedAI 8/10

Satellos changes primary endpoint in DMD trial after FDA talks

Satellos Bioscience (NASDAQ:MSLE, TSX:MSCL) revised its BASECAMP Phase 2 trial's primary endpoint to MRI-measured fat fraction, replacing dynamometry, after FDA feedback. The study tests forazapadin in boys with Duchenne muscular dystrophy. The company expects 12-week data in Q1 2027 and believes the new measure could support accelerated approval. Forazapadin targets AAK1, aiming to treat the disease regardless of mutation status.

investing.comNov 6

$MSLELow

A trial for boys with a muscle disease will track muscle fat on scans, not strength tests

Satellos Bioscience (NASDAQ: MSLE, TSX: MSCL) has updated its Phase 2 BASECAMP trial for Duchenne muscular dystrophy (DMD) to use MRI-measured fat fraction as the primary endpoint, replacing strength tests. The change follows FDA feedback and aims to support a potential accelerated approval pathway for forazapadin. Topline data is expected in Q1 2027. The company held a conference call to discuss the trial on Nov. 6, 2026.

stocktitan.netNov 6

$MSLEMed

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) completed enrollment for its Phase 2 BASECAMP trial of forazapadin for Duchenne muscular dystrophy. The trial, involving 18 sites globally, aims to assess safety, tolerability, and muscle force improvement. Satellos plans to share topline data in Q1 2027, adjusting from earlier plans to compile a comprehensive dataset.

globenewswire.comSep 30

$MSLEHighAI 9/10

Satellos stock jumps after FDA clears FSHD trial for forazapadin

Satellos Bioscience Inc (NASDAQ:MSLE) shares rose 6.8% premarket after FDA cleared its Investigational New Drug application for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD). The company plans a Phase 2 clinical study in Q4 2026. Forazapadin is also being evaluated for Duchenne muscular dystrophy.

investing.comSep 24